Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
About This Group of Stocks
Our Expert Thinking
BioNTech's massive vaccine success has created a financial powerhouse with the resources to revolutionise cancer treatment. This group captures companies at the forefront of mRNA and gene-based therapies, positioned to benefit as this technology expands beyond infectious diseases into oncology and other medical fields.
What You Need to Know
These are cutting-edge biotechnology companies specialising in genomic medicine, advanced drug delivery systems, and novel immunotherapies. They represent a growth-oriented, thematic investment opportunity that could disrupt traditional treatment approaches across multiple diseases.
Why These Stocks
Each company was handpicked by professional analysts for their role in the broader gene therapy ecosystem. With BioNTech's pivot into oncology proving the commercial viability of mRNA technology, these firms are positioned to capitalise on the expanding market for next-generation medical treatments.
Why You'll Want to Watch These Stocks
Revolutionary Technology Breakthrough
mRNA technology has proven its commercial power with COVID vaccines, and now it's expanding into cancer treatment and other diseases. You're watching the birth of a new medical era.
Massive Financial Backing
BioNTech's doubled revenues provide the capital firepower needed for groundbreaking research. This financial success is fuelling the next wave of gene-based therapies across the entire sector.
Expert-Curated Opportunities
These aren't random biotech picks. Each company was carefully selected by professional analysts for their role in the gene therapy revolution that's reshaping modern medicine.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AI Data Center Stocks: Infrastructure Buildout 2025
Microsoft's $4 billion investment in a new Wisconsin data center highlights the massive infrastructure buildout required for artificial intelligence. This creates a significant opportunity for companies that supply the essential components for these advanced facilities, from semiconductors to cooling and power systems.
SoftBank AI Pivot | Vision Fund Workforce Cuts Signal
SoftBank's Vision Fund is cutting its workforce to double down on artificial intelligence, signaling a major strategic shift. This pivot is expected to channel billions into capital-intensive AI infrastructure, creating a significant tailwind for companies involved in semiconductor manufacturing, data centers, and AI model development.
Live Entertainment Lawsuit: What's Next for Rivals
The FTC's lawsuit against Live Nation and Ticketmaster alleges monopolistic control and deceptive practices in the live event industry. This legal challenge could create significant opportunities for competing ticketing platforms and event promoters to gain market share.
Frequently Asked Questions
Everything you need to know about the product and billing.